Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

    ... Low karyotype complexity (by CC) and a high baseline platelet count (>280 × 109 /l) were associated with the achievement of ... important predictor for lenalidomide treatment failure was a platelet count <280 × 109 /l (Odds Ratio = 6·17, P = 0·040). This study ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

    ... Three of 4 patients had an improvement in their platelet count, and 3 of 3 had major improvement in abdominal pain/discomfort. The one patient whose platelet count did not respond had developed marrow failure, and she did well ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

    ... Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or ... reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction, or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Thrombocytopenia in patients with myelodysplastic syndromes.

    ... for increased risk of bleeding and delay of therapy. Platelet transfusions, although effective in increasing platelet counts, are limited by supply, are associated with risks, and result ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... to reduce bleeding events, decrease dependency on platelet transfusions and extend exposure to disease-modifying therapies. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution

    ... were closely associated with older age, higher platelet counts, lower lactate dehydrogenase levels, good-risk ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.

    ... mutations were closely associated with older age, higher platelet counts, and mutations of DNMT3A (36.4% vs. 8.7%, P<0.001), ASXL1 ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Thrombosis in paroxysmal nocturnal hemoglobinuria.

    ... will be discussed. Mechanisms explored include platelet activation, toxicity of free hemoglobin , nitric oxide ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.

    ... UD). All patients showed neutrophil and platelet engraftment . Cumulative incidence of acute (grade 2 or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study

    ... time was 142 days. In patients treated with BSC, platelet count alone was an independent prognostic factor. In younger ...

    Research Article last updated 07/20/2018 - 5:15pm.